Topically applied ascorbic acid solution for the treatment of basal cell carcinoma (BCC) - 21/06/16
Doi : 10.1016/j.jaad.2016.04.003
Péter Holló, MD, PhD, Hajnalka Jókai, MD, PhD, Judit Hársing, MD, Gyöngyvér Soós, PhD, Sarolta Kárpáti, MD, PhD, Krisztián Németh, MD, PhD ⁎ 
Department of Dermatovenerology and Dermatooncology, Semmelweis University, Budapest, Hungary
∗Correspondence to: Krisztián Németh, MD, PhD, Department of Dermatology, Medical College of Wisconsin, 920 W Wisconsin Ave, Milwaukee, WI, 53226Department of DermatologyMedical College of Wisconsin920 W Wisconsin AveMilwaukeeWI, 53226
| Drs Holló and Jókai contributed equally to this letter. |
|
| Dr Németh is currently affiliated with the Department of Dermatology, Medical College of Wisconsin, Milwaukee. |
|
| Funded by the Hungarian Scientific Research Fund (NOTKA 114460) and the Semmelweis University Dean's Research Award 2015. |
|
| Conflicts of interest: None declared. |
© 2016
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 75 - N° 1
P. 212-213 - juillet 2016 Retour au numéro
Article précédent
- Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions
- Zachary Nahmias, Vinod E. Nambudiri, Ruth Ann Vleugels
- Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC)
- Gina P. Kwon, Mina Sarah Ally, Irene Bailey-Healy, Anthony E. Oro, Jinah Kim, Anne Lynn Chang, Sumaira Aasi, Jean Y. Tang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?